DISCOUNT ZERTIFIKAT - BRISTOL-MYERS SQUIBB | Real-time Boerse Frankfurt Warrants 10:50:27 2024-06-18 am EDT | ||
| 35.68 EUR | -0.59% |
|
| Current month | +1.44% | ||
| 1 month | -4.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-18 | 35.68 | -0.59% |
| 24-06-17 | 35.89 | -1.64% |
| 24-06-14 | 36.49 | +0.41% |
| 24-06-13 | 36.34 | -1.20% |
| 24-06-12 | 36.78 | -1.47% |
Real-time Boerse Frankfurt Warrants
Last update June 18, 2024 at 10:50 am EDT
More quotesStatic data
| Product type | Discount Certificates |
|---|---|
| Buy / Sell | CALL |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD39R6 |
| ISIN | DE000VD39R63 |
| Date issued | 2024-04-18 |
| Maturity | 2025-03-21 (276 Days) |
| Parity | 1 : 1 |
| Emission price | 40.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.82 € |
|---|---|
| Lowest since issue | 34.82 € |
| Spread | 0.06 € |
| Spread % | 0.17% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.97
USD
Average target price
53.19
USD
Spread / Average Target
+29.84%
- Stock Market
- Certificates
- Certificat
